SillaJen (215600) Fundamentals 2026 — Revenue Analysis | SniperIQ
SillaJen (215600) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩275.7B, trading at ₩1996.00 on the KOE. This SniperIQ fundamentals page covers SillaJen's valuation, profitability (net margin -221.0%), revenue (₩9.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SillaJen's market cap?
SillaJen (215600) has a market capitalization of approximately ₩275.7B, trading at ₩1996.00 on the KOE. Market cap moves with the live share price.
What is SillaJen's P/E ratio?
SillaJen's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SillaJen?
SillaJen runs a net profit margin of -221.0%, a gross margin of -0.6%, and an operating margin of -239.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SillaJen generate?
SillaJen reported revenue of ₩9.2B for fiscal year 2025, with net income of -₩24.0B and earnings per share (EPS) of -175.95. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SillaJen pay a dividend?
SillaJen does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is SillaJen financially healthy?
SillaJen carries a debt-to-equity ratio of 0.02x and a current ratio of 15.81x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SillaJen a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SillaJen (215600) the key facts are: market cap ₩275.7B, revenue ₩9.2B, 52-week range 1960-5400. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SillaJen's full fundamentals live
Get SillaJen's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.